GL
ABBV icon

Graypoint LLC’s AbbVie ABBV Stock Holding History

Graypoint LLC’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$3.32M Sell
17,898
-34
-0.2% -$6.32K 0.19% 96
2025
Q1 		$3.76M Buy
17,932
+1,659
+10% +$323K 0.23% 84
2024
Q4 		$2.89M Sell
16,273
-1,247
-7% -$229K 0.18% 94
2024
Q3 		$3.46M Buy
17,520
+1,720
+11% +$321K 0.22% 82
2024
Q2 		$2.71M Buy
15,800
+1,094
+7% +$181K 0.19% 88
2024
Q1 		$2.68M Buy
14,706
+1,680
+13% +$290K 0.19% 97
2023
Q4 		$2.02M Sell
13,026
-2,135
-14% -$311K 0.16% 110
2023
Q3 		$2.26M Buy
15,161
+4,487
+42% +$659K 0.21% 91
2023
Q2 		$1.44M Sell
10,674
-1,667
-14% -$244K 0.14% 110
2023
Q1 		$1.97M Buy
12,341
+2,859
+30% +$437K 0.21% 89
2022
Q4 		$1.53M Sell
9,482
-1,214
-11% -$186K 0.18% 97
2022
Q3 		$1.44M Buy
10,696
+1,541
+17% +$221K 0.18% 99
2022
Q2 		$1.4M Sell
9,155
-839
-8% -$128K 0.18% 99
2022
Q1 		$1.62M Buy
9,994
+3,499
+54% +$508K 0.16% 104
2021
Q4 		$879K Buy
6,495
+1,241
+24% +$147K 0.09% 147
2021
Q3 		$567K Sell
5,254
-704
-12% -$80.4K 0.07% 161
2021
Q2 		$671K Buy
5,958
+826
+16% +$93K 0.09% 144
2021
Q1 		$555K Buy
5,132
+656
+15% +$70.2K 0.08% 150
2020
Q4 		$480K Buy
4,476
+710
+19% +$68.2K 0.08% 146
2020
Q3 		$330K Buy
3,766
+354
+10% +$33.3K 0.06% 155
2020
Q2 		$335K Buy
3,412
+326
+11% +$28.7K 0.08% 128
2020
Q1 		$235K Buy
+3,086
New +$263K 0.07% 135

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Graypoint LLC's ABBV Position: Q2 2025 in Review

Graypoint LLC reduced its AbbVie (ABBV) stake by 0.19% in Q2 2025, selling an estimated $6.32K and leaving 17,898 shares worth $3.32M. The position accounts for 0.19% of the portfolio, ranked #96.

Graypoint LLC first reported a position in ABBV in Q1 2020 and has held it in 22 quarters since. The position peaked at $3.76M in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

  • Graypoint LLC held 17,898 shares of AbbVie worth $3.32M as of Q2 2025.
  • Graypoint LLC sold 34 AbbVie shares in Q2 2025, an estimated $6.32K.
  • AbbVie made up 0.19% of Graypoint LLC's portfolio in Q2 2025, its #96 holding.
  • Graypoint LLC first reported a position in AbbVie in Q1 2020 and has held it in 22 quarters since.
  • Graypoint LLC's AbbVie position peaked at $3.76M in Q1 2025.
  • 3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Graypoint LLC's 13F filing for Q2 2025, filed 15 Jul 2025.